30 results about "Glycopyrronium bromide" patented technology

Aqueous formulations of indacaterol and glycopyrronium are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

The utility model relates to the technical field of pipettes, in particular to a pipette for glycopyrronium bromide neostigmine injection, which comprises a pipette main body, a sleeve is arranged at the bottom of the pipette main body, a movable clamping groove is arranged on the outer side of the sleeve, the inner wall of the top of the movable clamping groove is rotatably connected with a rotating screw rod, and a placing circular groove is arranged on the inner side of the movable clamping groove close to the top end. When the pipette main body sucks injection, the depth of the needle inserted into the injection is adjusted and fixed through the cooperation of the rotating screw rod, the limiting plate and other structures according to the height of the injection in a container, and the pipette main body is in a vertical state through the cooperation of the angle scale and other structures; therefore, it can be easily ensured that the insertion depth of the needle head is consistent every time, the pipette body is in a vertical state when the pipette body sucks injection, the accuracy of the pipette body in each time of pipetting is greatly improved, and the reliability of experimental results and the effectiveness of treatment are guaranteed.

Provided in the present invention are a suspended triple inhalation aerosol composition and a preparation method therefor. The aerosol composition comprises fluticasone furoate, vilanterol trifenatate, glycopyrrolate, a diluent, a surfactant and a propellant; has higher drug-delivery efficiency and drug-delivery dose, and higher lung deposition; and has the effects of better ameliorating Mch-induced elevated pulmonary resistance and decreased pulmonary compliance, thereby facilitating improvement to medication safety and patient compliance.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

The invention discloses a method for detecting the content of budesonide, formoterol and glycopyrronium bromide in budeagford inhalation aerosol, and relates to the technical field of drug detection and analysis, and the method comprises the following steps: preparing a test solution and a reference solution; detecting the contents of budesonide, formoterol and glycopyrronium bromide in the test solution and the reference solution by adopting a high performance liquid chromatography ultraviolet detector method; the detection conditions are as follows: octadecyl bonded silica gel is used as a filler, absolute ethyl alcohol-sodium dihydrogen phosphate solution is used as a mobile phase A, absolute ethyl alcohol-sodium dihydrogen phosphate solution-acetonitrile is used as a mobile phase B, and gradient elution is performed; the detection wavelength of the formoterol and the glycopyrronium bromide is 214 nm, and the detection wavelength of the budesonide is 254 nm. The detection method can simultaneously detect the contents of budesonide, formoterol fumarate and glycopyrronium bromide, has good specificity and high accuracy, and can effectively reduce the subsequent detection cost.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a detection method and application of related substances of glycopyrronium bromide neostigmine injection. The related substances of the glycopyrronium bromide neostigmine injection are detected by adopting a high performance liquid chromatography, taking an aqueous solution of potassium dihydrogen phosphate and sodium heptanesulfonate as a mobile phase A and taking acetonitrile as a mobile phase B for gradient elution. In addition, the content of related substances can be calculated according to a main component reference substance external standard method with correction factors. The detection method provided by the invention has relatively high specificity and sensitivity, and excellent precision, accuracy and durability.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

The utility model relates to the technical field of dilution preparation of injection, in particular to a dilution preparation device for glycopyrronium bromide neostigmine injection, which comprises a tank body, a tank cover is arranged at the top of the tank body, a sealing plate is arranged at the joint of the tank body and the tank cover, a first motor is arranged at the top of the tank cover, the output end of the first motor is fixedly connected with a rotating rod, and the rotating rod is fixedly connected with the tank cover. A plurality of lantern rings are arranged on the outer side of the rotating rod, stirring plates are symmetrically arranged on the outer sides of the lantern rings, and feeding nozzles are arranged between the lantern rings. The first motor drives the rotating rod to rotate, the rotating rod rotates to drive the lantern ring and the stirring plate to rotate together, and the stirring plate can be more conveniently detached through the lantern ring, so that the stirring plate is replaced and maintained; the first motor is used for driving the stirring plate to rotate at a low speed, so that injection in the tank body and diluent in the feeding box are stirred and mixed, and meanwhile, other diluent with a small dosage is added through the feeding spray head in the rotating rod.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

A method and formulation is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity.

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg / mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

An inhalation powder containing 24.1 μg of glycopyrronium bromide and 12.7 μg of formoterol fumarate dihydrate per unit dose is disclosed. The powder shows a clear bronchodilatory effect in patients with COPD after twice daily administration. After repeated administration, the lung function of the patients is significantly improved.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated canister, which formulation is particularly useful for use in pressurized metered dose inhalers for the treatment of respiratory diseases.

The invention provides application of glycopyrronium bromide in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of biological medicines. The research finds that the novel drug glycopyrronium bromide shows a clear and excellent technical effect in the aspect of treating nervous system diseases, on one hand, the glycopyrronium bromide can inhibit the inflammatory response of glial cells by reducing infiltration of central mononuclear macrophages (MDM); on the other hand, differentiation and maturation of oligodendroglia precursor cells (OPCs) into oligodendroglia cells can be effectively promoted, and the effect of promoting myelin sheath regeneration is achieved. Multiple sclerosis is effectively improved through the dual effects of inhibiting glial cell inflammation and promoting myelin regeneration, and the medicine is a candidate medicine with great potential for treating progressive multiple sclerosis (MS).

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

The utility model belongs to the production technology field of glycopyrronium bromide, specifically relates to a glycopyrronium bromide production waste treatment device. Including water washing bucket and alkali washing bucket, be linked to the connecting pipe between water washing bucket and alkali washing bucket, be equipped with the air inlet pipe on water washing bucket, be equipped with the exhaust pipe on alkali washing bucket, be equipped with water washing subassembly in water washing bucket, be equipped with high -efficient stirring subassembly in alkali washing bucket. The utility model discloses through the structure improvement, can carry out the adjustment of the stirring blade angle according to the concentration of the acid gas produced in the production process, and the small -angle stirring blade satisfies the stirring of small -density gas, and the big -angle stirring blade satisfies the stirring of high -density gas, can make motor release different power, effectively reduce the cost of use.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

Disclosed is a pharmaceutical composition for inhalation, comprising long-acting β2 agonist and long-acting muscarinic antagonist. The long-acting β2 agonist comprises olodaterol; or long-acting β2 agonist comprises arformoterol, and the pH of the composition is 3.5-5.5; or long-acting β2 agonist comprises indacaterol, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises revefenacin, and the pH of the composition is 3.5-5.5; or the long-acting muscarinic antagonist comprises glycopyrronium bromide, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises tiotropium bromide, and the pH of the composition is 2.0-4.0. Disclosed is a use of the pharmaceutical composition for inhalation for the preventing or treating of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and the like.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

To provide a formulation particularly useful for use in a pressurised metered dose inhaler for the treatment of respiratory diseases.SOLUTION: The present invention relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated can.SELECTED DRAWING: None

A pharmaceutical composition comprises a drug component. The drug component is a combination of one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone dipropionate, and one long acting beta-2-agonist (LABA) selected from formoterol and pharmaceutically acceptable salts thereof. The pharmaceutical composition also comprises a propellant component. The propellant component is at least 90 weight percent 1,1-difluoroethane (HFA-152a). The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents / co-solvents. The drug component is the sole drug component in the pharmaceutical composition.

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

The application belongs to the technical field of biological medicine, and relates to a medicine preparation, in particular to a capsule type inhalation powder aerosol and a preparation method thereof. The active ingredient of the capsule type inhalation powder aerosol is glycopyrronium bromide, the content of the glycopyrronium bromide in each capsule in terms of glycopyrronium is not higher than 20.0 mu g, and the FPF in the air dynamic characteristics is 50.0-75.0%. The capsule type inhalation powder aerosol provided by the application can significantly improve the drug safety on the premise of ensuring the drug efficacy.

The invention provides a liquid pharmaceutical composition comprising: a) at least one long-acting muscarinic receptor antagonist (LAMA) selected from the group consisting of glycopyrronium bromide, ipratropium bromide, umiclidium bromide, and revefenacin; b) at least one long-acting adrenoceptor agonist (LABA) selected from the group consisting of formoterol fumarate, salmeterol xinofoate; alformoterol tartarate, and vilanterol trifenate; and c) at least one inhaled corticosteroid (ICS) selected from the group consisting of beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, and fluticasone propionate; and wherein the composition is in the form of a solution for aerosolization, as well as methods and devices for use of the composition.

The utility model relates to the technical field of split charging equipment, in particular to a glycopyrronium bromide neostigmine injection split charging structure which comprises a split charging table, a plurality of openings are evenly formed in the top of the split charging table, a second air cylinder is arranged in each opening, a conical block is arranged at the output end of each second air cylinder, and a plurality of second sliding rods are evenly connected to the outer side of each conical block in a sliding mode. The other end of the second sliding rod is fixedly connected to the outer side of the bottom end of a clamping rod, a rotating shaft is arranged in the middle of the clamping rod, and fixing plates are arranged at the two ends of the rotating shaft. The second air cylinder is started to drive the conical block at the output end of the second air cylinder to move, when the conical block moves, the second sliding rod matched with the conical block can be driven to move by means of the shape of the conical block, and the clamping rod connected with the second sliding rod can be driven to rotate with the rotating shaft as the center through movement of the second sliding rod. When the clamping rod rotates, the first sliding rod moves in the sliding groove to play a guiding role, and the injection bottle at the top of the base plate is clamped through rotation of the clamping rod.